Oramed Pharmaceuticals to Present at the BIO International Convention in San Diego

 Oramed Pharmaceuticals to Present at the BIO International Convention in San

Company CEO to present on June 26, 2014, at 10:30am (PDT)

PR Newswire

JERUSALEM, June 23, 2014

JERUSALEM, June 23, 2014 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
clinical-stage pharmaceutical company focused on the development of oral drug
delivery systems, announced today that its Chief Executive Officer, Nadav
Kidron, will present at the 2014 BIO International Convention. This year's
global event for biotechnology will take place on June 23-26 at the San Diego
Convention Center in San Diego, California.

Presentation Details:

2014 BIO International Convention

Date: Thursday, June 26, 2014

Time: 10:30am Pacific Time

Location: San Diego Convention Center, Pacific Beach room

About the BIO International Convention

The BIO International Convention, the largest global event for the
biotechnology industry, will highlight the latest trends and the newest
opportunities for executives, investors, scientists, policy leaders, and media
from around the world. Speakers at the sessions will share breakthroughs in
medicine, diagnostics, the environment, energy production, business
operations, financing, partnerships, policy issues and food and agriculture.
The Convention also features the BIO Business Forum, a unique platform for
biotechnology and pharmaceutical companies, academic research institutions,
and investors from around the world to gather and discuss strategic
opportunities. For more information about the BIO International Convention
please visit convention.bio.org.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs currently delivered via injection. Established in 2006,
Oramed's Protein Oral Delivery (POD^[^TM^]) technology is based on over 30
years of research by top research scientists at Jerusalem'sHadassah Medical
Center. Oramed is seeking to revolutionize the treatment of diabetes through
its proprietary flagship product, an orally ingestible insulin capsule
(ORMD-0801) currently in separate Phase II clinical trials in patients with
both type 1 and type 2 diabetes under an Investigational New Drug (IND)
application with the U.S. FDA, and with its oral GLP-1 analog capsule
(ORMD-0901) entering IND-enabling studies later this year.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 and other federal securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates" and
similar expressions or variations of such words are intended to identify
forward-looking statements. For example, we are using forward-looking
statements when we discuss our clinical trials, including the timing thereof,
the effects of ORMD-0801 and oral insulin in general, and revolutionizing the
treatment of diabetes with our products. These forward-looking statements are
based on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection
for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required
to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely
develop and introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of acceptance of
our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our process; greater
cost of final product than anticipated; loss of market share and pressure on
pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals    
Aviva Guiloff        
Office: +972-2-566-0001 ext. 2
US: 1-718-831-2512 ext. 2
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
Press spacebar to pause and continue. Press esc to stop.